Exelixis, Inc. (Nasdaq: EXEL) today announced results for cabozantinib (CABOMETYX®) in combination with immunotherapies in patients with advanced colorectal cancer, including encouraging data from...
ImmVira's breakthrough product MVR-T3011 IV, global first clinical-stage oncolytic herpes simplex virus (oHSV) via intravenous injection, has recently completed first 2 cohorts dose-escalation of...
i2c Inc., a leading provider of digital payment and banking technology, announced that the company has been selected to power payment programs across nine...
ImmunityBio, Inc, a clinical-stage immunotherapy company, announced interim results (N=63) in its metastatic pancreatic cancer trial (QUILT 88) showing that the overall survival rate...
The Center for Breakthrough Medicines (CBM) and the University of Pennsylvania's Gene Therapy Program (GTP) have signed a landmark collaboration agreement, to combine Penn's...
